Author:
Lebwohl Mark,Strober Bruce,Schrader Amy,Li Alvin H.,Eckmann Thomas,Zhu Baojin,Malatestinic William N.,Birt Julie,Feely Meghan,Blauvelt Andrew
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72.
2. Honda H, Umezawa Y, Kikuchi S, Yanaba K, Fukuchi O, et al. Switching of biologics in psoriasis: reasons and results. J Dermatol. 2017;44(9):1015–9.
3. Bethlem JC, Janssens JAHM, Tijoe M. Real-world survival of brodalumab, in patients with psoriasis switched from ixekizumab: results of a single centre retrospective study (BroSwitch). J Eur Acad Dermatol Venereol. 2023;2(3):510–7.
4. Gottlieb AB, Lacour JP, Korman N, Wilhelm S, Dutronc Y, et al. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two phase III randomized studies. J Eur Acad Dermatol Venereol. 2017;31(4):679–85.
5. Deza G, Norario J, Lopez-Ferrer A, Vilarrasa E, Ferran M, et al. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J Eur Acad Dermatol Venereol. 2019;33(3):553–9.